Research And Development Tenders

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Contracts 2023

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Oh-Biologika-2023-15 - Dornase Alpha

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Original Discount Contracts 2023-15 - Beclometasone/Formoterol/Glycopyrronium Bromide (Combination of Active Substances)

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Vedolizumab, Atc L04aa33 for the Period 07/01/2023 - 06/30/2025

Open House Original Rebate Contracts 2023-18 - Rotigotine (Neupro(R); Atc N04bc09)

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Paragraph 8 Sgb V for the Ws Methylphenidate Hvw (Except 10 Mg/50 Pieces, 20 Mg/50 Pieces, 30 Mg/50 Pieces) Atc N06ba04 F. D. Time 07/01/23 - 06/30/25